This report highlights the importance of integrating molecular profiling into clinical decision-making and supports the rationale for expanding the use of HER2-targeted therapies beyond traditional HER2-positive classifications.(18) The aim of the study was to help guide future research and contribute to the growing field of precision oncology, especially in breast cancer management. This evidence concerns the gene ERBB2 and breast carcinoma.